TELO shareholders approve acquisition of Teli Pharma and increase share reserve to 11.5M

Telomir Pharmaceuticals, Inc.

Acquisition of Teli Pharmaceuticals approved; issuance of >20% new shares authorized.
2023 Omnibus Incentive Plan amended: share reserve increased from 6.5M to 11.5M shares and repricing allowed.
Bylaws amended to reduce quorum requirement to one-third of outstanding shares.
Directors elected: Erez Aminov, Matthew Whalen, Edward MacPherson, Matthew Del Giudice.
Ratification of Salberg & Company as independent auditor for FY 2025 approved.

item 5.02 item 5.03 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Telomir Pharmaceuticals, Inc.: Reduced quorum requirement for shareholder meetings to one-third (effective 2026-03-23).

Change: bylaw amendment
Effective: 2026-03-23

Exact text from the filing

the Company’s shareholders approved an amendment to the Bylaws of the Company to reduce the amount required for a quorum for an action by the Company’s shareholders adopted in a meeting to one-third.

View on SEC.gov

99 governance changes filed in the last 30 days. Browse all governance changes →

Telomir Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013240

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.